0000899243-22-021186.txt : 20220606
0000899243-22-021186.hdr.sgml : 20220606
20220606160601
ACCESSION NUMBER: 0000899243-22-021186
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220531
FILED AS OF DATE: 20220606
DATE AS OF CHANGE: 20220606
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stants Kristen
CENTRAL INDEX KEY: 0001805727
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38541
FILM NUMBER: 22998107
MAIL ADDRESS:
STREET 1: C/O MAGENTA THERAPEUTICS, INC.
STREET 2: 100 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Magenta Therapeutics, Inc.
CENTRAL INDEX KEY: 0001690585
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 TECHNOLOGY SQUARE
STREET 2: 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-201-2700
MAIL ADDRESS:
STREET 1: 100 TECHNOLOGY SQUARE
STREET 2: 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-31
0
0001690585
Magenta Therapeutics, Inc.
MGTA
0001805727
Stants Kristen
C/O MAGENTA THERAPEUTICS, INC.
100 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
0
1
0
0
Chief People Officer
Common Stock
2022-05-31
5
A
0
E
3000
0.99
A
17264
D
The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of December 1, 2021 through May 31, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 31, 2022.
/s/ Cindy Driscoll, Attorney-in-Fact for Kristen Stants
2022-06-06